

Lead generation of a first-in-class CD171 ADC against solid tumors

APITBIO, Inc.



ONCOLOGY	Lead
Product Type	Drug-conjugate
Indication	CD171 (L1CAM)-positive Solid tumor
Target	CD171 (L1CAM)
MoA(Mechanism of Action)	Binding to CD171 (L1CAM) → Internalization → Cleaved and released active payload in lysosome → Cancer cell death by payload
Competitiveness	<ul style="list-style-type: none"> • Class: First-in-class. • Anti-CD171 mAb (Ab612): Phase I IND approval in KOREA, Completion of GMP production process in 500 L scale. • Ab612-MMAE (IC₅₀): 100-fold lower than Kadcyra in HER2 (+) breast cancer cells, Excellent cytotoxicity in HER2 (low) and TNBC cells. • Ab612-MMAE, Ab612-Dxd: Similar in vivo efficacy with Enhertu in JIMT-1-bearing CDX mouse model, Excellent stability.
Development Stage	Lead
Route of Administration	Intravenous infusion